Search

Your search keyword '"Junki Toyosawa"' showing total 10 results
Start Over Author "Junki Toyosawa"
10 results on '"Junki Toyosawa"'

1. Resection depth for small colorectal polyps comparing cold snare polypectomy, hot snare polypectomy and underwater endoscopic mucosal resection

Author

Junki Toyosawa, Yasushi Yamasaki, Tsuyoshi Fujimoto, Shouichi Tanaka, Takehiro Tanaka, Toshiharu Mitsuhashi, and Hiroyuki Okada

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and study aims Small colorectal polyps are removed by various methods, including cold snare polypectomy (CSP), hot snare polypectomy (HSP), and underwater endoscopic mucosal resection (UEMR), but the indications for using these methods are unclear. We retrospectively assessed the efficacy of CSP, HSP, and UEMR for small polyps, focusing on the depth of the resected specimens. Patients and methods Outpatients with non-pedunculated small polyps (endoscopically diagnosed as 6 to 9 mm), resected by two endoscopists between July 2019 and September 2020, were enrolled. We histologically evaluated the specimens resected via CSP, HSP, and UEMR. The main outcome was the containment rate of the muscularis mucosa (MM) and submucosa (SM) tissues. Results Forty polyps resected via CSP (n = 14), HSP (n = 12), or UEMR (n = 14) were enrolled after excluding 13 polyps with resection depths that were difficult to determine. The rates of specimens containing MM and SM tissue differed significantly (57 % and 29 % for CSP, 92 % and 83 % for HSP, and 100 % and 100 % for UEMR, respectively (P = 0.005 for MM and P

Published
2022
Full Text
View/download PDF

2. Modified line-assisted complete closure of the defect after gastric endoscopic full-thickness resection: a pilot study in porcine models

Author

Yasushi Yamasaki, Masayasu Ohmori, Junki Toyosawa, Soichiro Ako, and Hiroyuki Okada

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and study aims Closure after endoscopic full-thickness resection (EFTR) is challenging. We previously developed a simple endoscopic closure method: line-assisted complete closure (LACC). We performed a pilot study using porcine models to evaluate the feasibility of modified LACC after gastric EFTR. Patients and methods Six live pigs were included. EFTR (greater curvature of the gastric antrum [n = 3] and anterior wall of the gastric body [n = 3]) was performed under general anesthesia and the defect after EFTR was closed by modified LACC. The pigs were observed until postoperative day 4 (Day 4). The closure site was endoscopically evaluated and the presence or absence of peritonitis and fluid leakage was evaluated. The outcomes were the success rate of modified LACC on the day of the procedure, maintenance of defect closure, presence of peritonitis or leakage, and clinical course. Results Once complete closure was successfully achieved in all cases, maintenance of closure on Day 4 was not achieved. However, there was neither peritonitis nor fluid leakage. The defect was completely covered by surrounding tissues on Day 4 and the clinical course was good in all cases. Conclusions The feasibility of modified LACC after gastric EFTR was demonstrated in porcine models. Further improvement is needed to maintain defect closure.

Published
2022
Full Text
View/download PDF

3. Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy

Author

Tomo Kagawa, Shigenao Ishikawa, Tomoki Inaba, Mariko Colvin, Junki Toyosawa, Yuki Aoyama, Masaya Ishida, Sakiko Kuraoka, Kunio Okamoto, Ichiro Sakakihara, Koichi Izumikawa, Kumiko Yamamoto, Sakuma Takahashi, Shigetomi Tanaka, Mihoko Matsuura, Toshimi Hasui, Masaki Wato, Midori Ando, Satoko Nakamura, and Koichi Mizobuchi

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and study aims Salvage therapy for esophageal cancer following chemo-radiation therapy (CRT) has not been established. We aimed to evaluate endoscopic submucosal dissection (ESD) as a salvage therapy based on histopathological features of lesions. Patients and methods We compared 10 lesions in eight patients with local residual, recurrent, or metachronous esophageal squamous cell carcinoma treated by ESD after CRT (CRT group) and 59 lesions treated by ESD without CRT (non-CRT group) during the same period. Results The en bloc resection rate was 100 % while the complete resection rate was 80.0 % in the lesions after CRT, indicating no difference between the CRT and non-CRT groups. Pathological examination showed that fibrosis was more intense in the lamina propria mucosa, muscularis mucosa, and submucosa. The muscularis mucosa was thicker in both non-tumor and tumor sites in the CRT group compared to the non-CRT group. However, severe submucosal fibrosis was observed only in one lesion in the CRT group. The maximum diameter of the submucosal artery was significantly larger in the CRT group (P

Published
2018
Full Text
View/download PDF

4. DIAGNOSTIC POINTS OF COLORECTAL SESSILE SERRATED LESION WITH DYSPLASIA

Author

Kensuke Takei, Keita Harada, Junki Toyosawa, Yuki Aoyama, Shumpei Yamamoto, Eriko Yasutomi, Shouko Igawa, Keiko Takeuchi, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Sakiko Hiraoka, Takehiro Tanaka, and Hiroyuki Okada

Subjects
Gastroenterology, Radiology, Nuclear Medicine and imaging
Published
2022

5. Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy

Author

Shigetomi Tanaka, Sakiko Kuraoka, Midori Ando, Tomo Kagawa, Sakuma Takahashi, Kunio Okamoto, Toshimi Hasui, Koichi Mizobuchi, Satoko Nakamura, Koichi Izumikawa, Shigenao Ishikawa, Junki Toyosawa, Masaya Ishida, Mariko Colvin, Yuki Aoyama, Ichiro Sakakihara, Masaki Wato, Mihoko Matsuura, Kumiko Yamamoto, and Tomoki Inaba

Subjects
Original article, medicine.medical_specialty, Muscularis mucosae, genetic structures, Salvage therapy, Lesion, 03 medical and health sciences, 0302 clinical medicine, Fibrosis, Submucosa, medicine, Pharmacology (medical), cardiovascular diseases, lcsh:RC799-869, Lamina propria, business.industry, Esophageal cancer, medicine.disease, Dissection, medicine.anatomical_structure, 030220 oncology & carcinogenesis, cardiovascular system, lcsh:Diseases of the digestive system. Gastroenterology, 030211 gastroenterology & hepatology, Radiology, medicine.symptom, business, therapeutics, circulatory and respiratory physiology
Abstract

Background and study aims Salvage therapy for esophageal cancer following chemo-radiation therapy (CRT) has not been established. We aimed to evaluate endoscopic submucosal dissection (ESD) as a salvage therapy based on histopathological features of lesions. Patients and methods We compared 10 lesions in eight patients with local residual, recurrent, or metachronous esophageal squamous cell carcinoma treated by ESD after CRT (CRT group) and 59 lesions treated by ESD without CRT (non-CRT group) during the same period. Results The en bloc resection rate was 100 % while the complete resection rate was 80.0 % in the lesions after CRT, indicating no difference between the CRT and non-CRT groups. Pathological examination showed that fibrosis was more intense in the lamina propria mucosa, muscularis mucosa, and submucosa. The muscularis mucosa was thicker in both non-tumor and tumor sites in the CRT group compared to the non-CRT group. However, severe submucosal fibrosis was observed only in one lesion in the CRT group. The maximum diameter of the submucosal artery was significantly larger in the CRT group (P Conclusions Compared to the non-CRT group, the lesions in the CRT group were accompanied by fibrosis while the muscularis mucosa were thicker; however, severe fibrosis of the submucosa was rare. It is important to dissect the muscularis mucosa appropriately during ESD, which makes successful dissection of the submucosa possible. Attention should be paid to bleeding from large arteries.

Published
2018

7. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

Author

Kenji Kuwaki, Kazuhide Yamamoto, Hideaki Kinugasa, Hidenori Shiraha, Takeshi Tomoda, Shinichiro Nakamura, Junki Toyosawa, Kazuhiro Nouso, Akinobu Takaki, Yasuhiro Miyake, Fusao Ikeda, Koji Miyahara, Hiroaki Hagihara, Sayo Kobayashi, and Hideki Onishi

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, biology, business.industry, Hepatitis C virus, Hazard ratio, Gastroenterology, medicine.disease, medicine.disease_cause, Tumor progression, Hepatocellular carcinoma, Internal medicine, biology.protein, Medicine, Biomarker (medicine), Thrombus, business, human activities, Follistatin
Abstract

Background and aim Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661 pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P = 0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio = 2.41, 95% confidence interval = 1.16-5.00, P = 0.02). Conclusions Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

Published
2013

8. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

Author

Takeshi, Tomoda, Kazuhiro, Nouso, Koji, Miyahara, Sayo, Kobayashi, Hideaki, Kinugasa, Junki, Toyosawa, Hiroaki, Hagihara, Kenji, Kuwaki, Hideki, Onishi, Shinichiro, Nakamura, Fusao, Ikeda, Yasuhiro, Miyake, Hidenori, Shiraha, Akinobu, Takaki, and Kazuhide, Yamamoto

Subjects
Adult, Aged, 80 and over, Male, Follistatin, Carcinoma, Hepatocellular, Liver Neoplasms, Enzyme-Linked Immunosorbent Assay, Middle Aged, Prognosis, Biomarkers, Tumor, Humans, Female, Aged, Follow-Up Studies, Forecasting
Abstract

Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed.Serum was collected from 162 patients (91 hepatocellular carcinoma [HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients.Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661 pg/mL, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels (P = 0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio = 2.41, 95% confidence interval = 1.16-5.00, P = 0.02).Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results